Targets › GABBR2
6 programs from 6 companies in 7 trials: 4 Phase 2, 2 Phase 3, 1 Phase 4; Psychiatry, Other, Neurology; next expected readout Dec 2026.
Component of a heterodimeric G protein-coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. (UniProt, O75899)
Open in Phaseline: the race on GABBR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | Low Sodium Oxybate GABA-B receptor agonist; sodium and salt-balanced formulation of sodium oxybate | GABBR1, GABBR2 | Phase 4 | Idiopathic Hypersomnia | Jan 2027 |
| Hospital General Universitario Gregorio Marañon | Arbaclofen GABA-B receptor agonist | GABBR1, GABBR2 | Phase 3 | Autism Spectrum Disorders | Dec 2026 |
| Tanta University | Baclofen GABA-B receptor agonist | GABBR1, GABBR2 | Phase 3 | Post Operative Pain | – |
| Hospices Civils de Lyon | Baclofen GABA-B receptor agonist | GABBR1, GABBR2 | Phase 2 | Benzodiazepine Dependence | Oct 2028 |
| Adnan Imtiaj Rahul | Baclofen GABA-B receptor agonist | GABBR1, GABBR2 | Phase 2 | GERD - PPI Non-responders | – |
| Children's Hospital Medical Center, Cincinnati | Baclofen GABA-B receptor agonist | GABBR1, GABBR2 | Phase 2 | Fragile X Syndrome | – |
Benzodiazepine Dependence (2) Idiopathic Hypersomnia (1) Autism Spectrum Disorders (1) GERD - PPI Non-responders (1) Post Operative Pain (1) Fragile X Syndrome (1)
small molecule (6)
Mayo Clinic (1) Hospital General Universitario Gregorio Marañon (1) Adnan Imtiaj Rahul (1) Hospices Civils de Lyon (1) Tanta University (1) Children's Hospital Medical Center, Cincinnati (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.